tbuckley/cabot-search huggingface dataset:
Non-dermatophytes in onychomycosis of the toenails
Authors: D.H. ELLIS, A.B. WATSON, J.E. MARLEY, T.G. WILLIAMS
Journal: British Journal of Dermatology (1997)

A multicentre trial for the treatment of dermatophyte onychomycosis of the toenails with terbinafine was carried out in Australia and New Zealand. Between eight and 12 nail samples were obtained from each of the 118 patients in the 48-week trial, and each sample was investigated by direct microscopy and culture for dermatophyte and non-dermatophyte fungi. Patients were randomized to treatment with terbinafine at 250 mg/day or placebo for the first 12 weeks of the study, then non- responders were offered a 12-week course of terbinafine from week 28. All patients had a dermatophyte infection. In 42 patients (36%) microscopy and mycological culture identified dermatophytes alone. In the remaining 76 patients (64%), a non-dermatophyte mould or yeast was also isolated at some stage during the trial, but in only three patients did the same non- dermatophyte persist in two or more successive nail specimens. The presence of a fungal con- taminant in addition to a dermatophyte had no apparent effect on the efficacy of treatment with terbinafine. We conclude that non-dermatophyte moulds and yeasts are generally found as contaminating organisms in dermatophyte onychomycosis, secondary to the dermatophytes, and that they do not infiuence the outcome of treatment.
Psychiatric care and patient confidentiality
Authors: L. Hoffman
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Authors: R Pallister, J Walton, I Seymour, H Jory, B Scott, R Price, A Horler, W Brabbin, S Curwen, A Mackinnon, W Ashby, G Rees, R Stewart, J Maior, T Challenger, K Cowan, T Begg, S Mattingley, T Mitchell, N Maclean, A Dickson, R Clark, E Robinson, J Evans, I Walters
Journal: BMJ (1966)

U.S.A. if required.An all-in two-week tour of the east coast would cost approximately £140 per person.Only members of the Metropolitan Counties Branch and their immediate family qualify for inclusion in the chartered flight.The Camden Division was formed on 10 June 1965 from the old St. Pancras and Hampstead Divisions of the B.M.A., and includes all the area of the new Greater Lon- -don Borough of Camden except the part that was originally Holborn.
Physicians may Testify as to Matters Gained from the Study of Books.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EMIAT substudy: Prediction of the efficacy of amiodarone by heart rate turbulence Georg Schmidt, Petra Barthel, Raphael Schneider, Albert Schomig, John Camm, Marek Malik. Technische Universit�t M�nchen, Munich, Germany, St. George's Hospital Medical School, London, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
Letter: The treatment of Graves disease
Authors: Fereidoun Azizi
Journal: JAMA (1974)

<h3>To the Editor.—</h3> The authors cited the paper by Nofal et al to demonstrate the high incidence of hypothyroidism following radioactive iodine therapy, but failed to mention that in the same study the rate of thyroid hypofunction ten years after subtotal thyroidectomy was 43%. Although it is generally agreed that the incidence of hypothyroidism is higher following iodine 131 therapy than after surgery, the difference is not tremendous. Furthermore, recent study by Wood, Peterson, and Ingbar concludes that progressive impairment of thyroid function is a frequent termination of the natural history of Graves disease. Thus, untreated patients, as well as those treated with radioactive iodine administration or subtotal thyroidectomy, may develop hypothyroidism that can be adequately managed with daily administration of one tablet of a thyroid preparation. Recurrence of hyperthyroidism occurs in up to 17.2% of patients with Graves disease who undergo thyroidectomy (Hershman), while 90% of patients are cured
Association of Sexual Intercourse With Sudden Cardiac Death in Young Individuals in the United Kingdom
Authors: Gherardo Finocchiaro, Joseph Westaby, Elijah R. Behr, Michael Papadakis, Sanjay Sharma, Mary N. Sheppard
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Purifying Selection Determines the Short-Term Time Dependency of Evolutionary Rates in SARS-CoV-2 and pH1N1 Influenza
Authors: Mahan Ghafari, Louis du Plessis, Jayna Raghwani, Samir Bhatt, Bo Xu, Oliver G Pybus, Aris Katzourakis
Journal: Molecular Biology and Evolution (2022)

Abstract High-throughput sequencing enables rapid genome sequencing during infectious disease outbreaks and provides an opportunity to quantify the evolutionary dynamics of pathogens in near real-time. One difficulty of undertaking evolutionary analyses over short timescales is the dependency of the inferred evolutionary parameters on the timespan of observation. Crucially, there are an increasing number of molecular clock analyses using external evolutionary rate priors to infer evolutionary parameters. However, it is not clear which rate prior is appropriate for a given time window of observation due to the time-dependent nature of evolutionary rate estimates. Here, we characterize the molecular evolutionary dynamics of SARS-CoV-2 and 2009 pandemic H1N1 (pH1N1) influenza during the first 12 months of their respective pandemics. We use Bayesian phylogenetic methods to estimate the dates of emergence, evolutionary rates, and growth rates of SARS-CoV-2 and pH1N1 over time and investigate how varying sampling window and data set sizes affect the accuracy of parameter estimation. We further use a generalized McDonald–Kreitman test to estimate the number of segregating nonneutral sites over time. We find that the inferred evolutionary parameters for both pandemics are time dependent, and that the inferred rates of SARS-CoV-2 and pH1N1 decline by ∼50% and ∼100%, respectively, over the course of 1 year. After at least 4 months since the start of sequence sampling, inferred growth rates and emergence dates remain relatively stable and can be inferred reliably using a logistic growth coalescent model. We show that the time dependency of the mean substitution rate is due to elevated substitution rates at terminal branches which are 2–4 times higher than those of internal branches for both viruses. The elevated rate at terminal branches is strongly correlated with an increasing number of segregating nonneutral sites, demonstrating the role of purifying selection in generating the time dependency of evolutionary parameters during pandemics.
St. Mary's Hospital
Authors: C. H. Jones
Journal: BMJ (1861)

February 26th, with chorea pretty severe; tongue rough and white; pulse excited, weak.He has been affected two months, in consequence of fright at seeing a man hang hituself.He had chorea three years ago.The right side is most disordered.Treated at first by car- bonate of iron and cold douche, subsequently by liquor potassme arsenitis, he got gradually better; but the influence of remedies was not marked.CASE ii.E. NI., aged 10, female, admitted April 12th with chorea, which at first affectedl the right side most, but lhad become general.She used to start and wake up at night in fright.Catamenia regular; bowels regular.No worms.Some psoriasis on lower lip.Treatment for fourteen days by liquor potassae arsenitis, without advantage; afterwards by one-twentieth of a grain of strychnia three times daily, under which she got well in five or six weeks.CASE III.E. C., aged 12, female, was about six months under treatment for psoriasis, in the course of which chorea showed itself, affecting the right leg and arm.Under liquor potassae arsenitis and an issue in the right arm, botlh disorders got wvell.CASE iv.H. L., aged 10, male, was a(dmitted April lth with sevele chorea; " is not still a moment".He had been ill fourteen days.Liquor potassTe arsenitis was given for a week, and castor oil.Lichen urticatus theni appeared.Halt a grain of ammonio-sulphate of copper was given three times daily.April 30)th.No improvement.Eruption same.One- twenty-fourth of a grain of strychnia was given thrice daily; this was continued, atter fourteen days, four times a day till July 9th, when botlh chorea and eruption were muchl improved.He ceased attendance August 20th, wlen he was free from chorea, but had still some eruption.CASE V. C. W., aged 12, female, was admitted Nov. 24th.She had been ill three weeks with markled chorea.Circulation languid.She was treated by the carbonates of iron and ammonia, with valerian ; and was cured in abouit a month.CASE vi.E. W., aged 13, female, was admitted Dec. 29th.Ill four weeks.The left side is affected; the arm feels weak, and twitches at times ; and the three inner fingers feel numb, and get contracted.The lecg is at times jerked out; it is less strong thani the other.The mouth is occasionally drawn to the left; speech altered.Mlernory not so good as formerly; is very forgetful and languid.Head giddy this morning.No catamenia yet.Treated at first by carbonate of ammonia, ammoniocitrates of iron, infusion of valerian; and subsequently by strychnia and tincture of sesquichloride of iron.By Feb. 13th she was well enough to be discharged.CASE; VII.IV. C. P., aged 15, male, was admitted April 23rd, with chorea affectin, right side, arm, leg, and face.Speech interfered with.Bowels regular.He ha(l been ill thlree weeks.Treated by carbonate of armmonia, ainimionio-citrate of iron, tincture of henbane, infusion of valerian ; subsequently by strychnia and quinine.He improved under botlh, but was not well when he ceased attendance.CASE VIII.
Tell Me
Authors: Iris Wagman Borowsky
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Reliability and accurate quantification of left ventricular size and function by ultrafast (freehand) three-dimensional echocardiography in patients with normal and abnormal left ventricles: Comparison with magnetic resonance imaging Stefano De Castro, Antonio Pelliccia, Laura Vitali Serdoz, Marcello De Santis, Rachele Adorisio, Federica Papetti, Cristian Di Russo, Francesco Fedele, Natesa Pandian. Department of Cardiovascular and Respiratory Sciences, ?La Sapienza? University, Rome, Italy, …
Journal: Journal of the American College of Cardiology (2001)
Preventive medicine
Authors: C. G. Sheps
Journal: JAMA (1979)

The continuously rising cost of medical care and the recognition that these increased expenditures do not seem to be accompanied by commensurate gains in the health status of the population have helped to focus our attention on disease before it happens, ie, on prevention. At the same time, we have learned a great deal about the factors that produce or are associated with the leading causes of death and disability. Evidence mounts to implicate personal behavior and the physical and socioeconomic environment as prime determinants of health and disease; hence, the rising interest in health policy discussions. I shall broadly sketch the objectives, scope, problems, and challenges in the types of programs of prevention now emerging.<sup>1</sup> <h3>Levels of Prevention</h3> Prevention measures are either primary or secondary. Primary prevention consists of those actions that prevent a disease from occurring. Secondary prevention consists of activities designed to detect disease before it
NCCN News
Journal: Journal of the National Comprehensive Cancer Network (2010)

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines) for Breast Cancer to affirm the recommendation regarding the use of bevacizumab (Avastin, Genentech/ Roche) in the treatment of metastatic breast cancer.The NCCN Guidelines Panel for Breast Cancer affirmed its existing recommendation of bevacizumab in combination with paclitaxel (Taxol, Bristol-Myers Squibb Company) as an appropriate therapeutic option for metastatic breast cancer with the evidence designation 2A meaning that it is based on lower level evidence and uniform agreement of the panel as to its appropriateness.The Panel revised the related footnote to read, "Randomized clinical trials in metastatic breast cancer document that the addition of bevacizumab to some first or second line chemotherapy agents modestly improves time to progression and response rates but does not improve overall survival.The time to progression impact may vary among cytotoxic agents and appears greatest with bevacizumab in combination with weekly paclitaxel."The NCCN Guidelines are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of expert physicians from NCCN Member Institutions.The most recent version of this and all the NCCN Guidelines are available free of charge at NCCN. org.
Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.
Authors: Maria Diab, Subir Goyal, Jeffrey M. Switchenko, Olatunji B. Alese, Walid Labib Shaib, Mehmet Akce, Christina Wu, Bassel F. El-Rayes
Journal: Journal of Clinical Oncology (2022)

194 Background: Patients (pts) with multiple synchronous colon cancer primaries (MCPs) constitute a unique subset of pts with colon cancer. However, there are limited published studies about these pts. The objective of this study is to compare the characteristics and outcomes of pts with MCPs to those with single colon cancer primaries (SCPs) using the largest study population to date. Methods: Data was obtained from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. Pts with synchronous MCPs were included and were matched 1:3 with pts with SCPs based on the Coarsened Exact Matching method for age, gender, and race. Only patients with multiple synchronous primaries were included (time since index = 0 months). We excluded pts with a lag time since diagnosis of index primary of 1 month or more. Univariate (UNA) and multivariable (MVA) analyses were performed to identify factors associated with patient outcomes. Kaplan-Meier analyses and Cox proportional hazards models were used to assess the association between tumor/patient characteristics and overall survival (OS). Results: A total of 3322 pts with MCPs and 9966 pts with SCPs were identified. Median age was 71 years. Majority were male (51.5%) and White (80.1%). 73.4% and 69.6% of pts had 12 or more lymph nodes examined for the MCPs and SCPs cohorts, respectively. The SCPs cohort included more T4 stage and more well- and moderately-differentiated histology. OS was significantly shorter in MCPs compared to SCPs (HR 1.29; 1.22-1.36; p &lt; 0.001), with a 5- and 10-year OS rate of 47.8% and 28.2% for the MCPs and 56.4% and 41.6% for the SCPs, respectively, for all stages combined. In the MCPs cohort, the use of adjuvant chemotherapy was associated with an improved survival in AJCC stages II, III, and IV but not stage I. Conclusions: This is the largest study evaluating the impact of MCPs on outcomes. Across stages II to IV, pts with MCPs have a shorter survival than those with SCPs. Pts with stage II MCPs who receive adjuvant chemotherapy derive a survival benefit. Current guidelines do not list multiple synchronous primaries as a high-risk feature for stage II.
SOCIETY NEWS.
Authors: W. P. Carr
Journal: JAMA (1897)

<h3>Western Surgical and Gynecological Association.</h3> —The sixth annual session of the Western Surgical and Gynecological Association was held in the Senate chamber of the State House at Topeka, Kan., Dec. 28 and 29, 1896. It was one of the best meetings in the history of the Association, being largely attended, having a good program and interesting discussions. In welcoming the surgeons on behalf of Topeka Mayor Fellows said in part: "To welcome to Topeka honored members of the most progressive of all professions is indeed a pleasure. Five years ago a few prominent surgeons met in this city and started your organization. Today it embraces among its members the leading surgeons of the West. Great as has been the growth of your Association in members and influence, it is as nothing compared to the wonderful progress of the profession you so worthily represent. During the century that is nearing the
Recommendations for Protecting Human Health Against Potential Adverse Effects of Long-term Exposure to Low Doses of Chemical Warfare Agents
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EVALUATION OF THE EFFICACY AND SAFETY OF OTAMIXABAN VERSUS UNFRACTIONATED HEPARIN+EPTIFIBATIDE IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES BY PCI IN THE SEPIA-ACS1 TIMI 42 TRIAL
Authors: Christian T. Ruff, Angele Moryusef, Amarachi Umez-Eronini, Elaine Hoffman, Christophe Gaudin, Elliott Antman, Marc Sabatine
Journal: Journal of the American College of Cardiology (2013)
Severe Isoniazid-Associated Hepatitis— New York, 1991-1993
Journal: JAMA (1993)

In November 1992, the New York State Department of Health was notified of a patient who underwent liver transplantation because of severe hepatitis that developed during the use of isoniazid (INH) preventive therapy (IPT) for latent tuberculous infection. Inquiry at liver transplant centers in New York revealed other patients who had hepatitis attributed to INH. This report summarizes findings of the ongoing investigation into the extent and causes of this problem.